SPOTLIGHT -
Slideshow
Author(s):
Following TBI, cognitive deficits, comorbid medical and neurological problems, as well as complex pharmacotherapeutic needs and sensitivities frequently complicate evaluation and treatment of psychosis in this population.
April in Review: Updates on the Psychiatric Treatment Pipeline
Treating ‘Morally Objectionable’ Patients
Cobenfy as Add-On Treatment for Schizophrenia Fails to Meet Primary Endpoint in Phase 3 ARISE Trial
What Will the Future of Alzheimer Disease Treatment Look Like?
The Slow Road to Psychosis
Diagnostic Considerations in Clinical Cognitive Assessment